Currently, ERK or MEK inhibitors are considered mainly for the treatment of NB tumors with activating RAS mutations, which constitute a very aggressive NB subtype, but are relatively rare (<1% of primary tumors) [5, 44]. The gene discussed is MAP2K7; the disease is neuroblastoma.